Cladribine as monotherapy or combined with dexamethasone and idarubicin or mitoxantrone in previously treated patients with low-grade lymphoid malignancies.
نویسندگان
چکیده
Haematologica vol. 85(2):February 2000 mia. Cancer Genet Cytogenet 1981; 4:138-42. 4. Knapp RH, Dewald GW, Pierre RV. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 1985; 60: 507-16. 5. Mertens F, Johansson B, Heim S, Kristofferson U, Mitelman F. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature. Leukemia 1991; 5:214-20. 6. Morris CM, Fitzgerald PH, Hollings PE, et al. Essential thrombocythaemia and the Philadelphia chromosome. Br J Haematol 1988; 70:13-9. 7. Corradini P, Palumbo AP, Battaglio S, Ponzio G, Boccadoro M, Pileri A. Analysis of the breakpoint cluster region in essential thrombocythemia. Haematologica 1990; 75:573-5. 8. Blickstein D, Aviram A, Luboshitz J, et al. BCR-ABL transcripts in bone marrow aspirates of Philadelphianegative essential thrombocythemia patients: clinical presentation. Blood 1997; 90:2768-71. 9. Marasca R, Luppi M, Zucchini P, Longo G, Torelli G, Emilia G. Might essential thrombocythemia carry Ph anomaly? Blood 1998; 91:3084-5. 10. Hackwell S, Ross F, Cullis JO. Patients with essential thrombocythemia do not express BCR-ABL transcripts. Blood 1999; 93:2420-1.
منابع مشابه
Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
The aim of our study was to determine the effectiveness and toxicity of combined chemotherapy consisting of cladribine (2-chloro-deoxyadenosine, 2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in the treatment of refractory or relapsed indolent lymphoproliferative disorders. The treatment course consisted of 2-CdA given at a dose of 0.12 mg/kg/24 h in a 2-h intravenous infusion for 5 (C...
متن کاملReduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
Cladribine (2-chlorodeoxyadenosine) (2-CdA) has been shown to be effective in mantle-cell (MCL) and low-grade lymphomas (lgNHL). The aim of this multicentre study was to evaluate the rate and duration of remissions and to examine the toxicity of the combination of reduced-dose 2-CdA and mitoxantrone (CdM) in MCL and lgNHL as first-line therapy or for patients in their relapse. A total of 285 co...
متن کاملCladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study.
Cladribine is approved to be used in 24-hour continuous infusion for the treatment of low-grade lymphoma by the Ministry of Health, Labor and Welfare in Japan. Pharmacokinetic studies showed that the antitumor activity of cladribine by 2-hour infusion should be comparable to that given by continuous infusion. The safety and anti-tumor activity of short infusion of cladribine was shown in hairy ...
متن کاملThe effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil.
We present the long-term follow-up and results of subsequent treatments in patients with chronic lymphocytic leukemia treated initially with cladribine + prednisone or chlorambucil + prednisone in a randomized, cross-over study. We found higher complete and overall responses rates in patients who received cladribine + prednisone as first and second-line treatment but no significant differences ...
متن کاملCombined Intratympanic and Systemic Steroid Therapy for Poor-Prognosis Sudden Sensorineural Hearing Loss
Introduction: The aim of this study was to evaluate the efficacy of combined intratympanic and systemic steroid therapy compared with systemic steroid therapy alone in idiopathic sudden sensorineural hearing loss (ISSNHL) patients with poor prognostic factors. Materials and Methods: Seventy-seven patients with sudden sensorineural hearing loss (SSNHL) who had at least one poor prognostic fa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Haematologica
دوره 85 2 شماره
صفحات -
تاریخ انتشار 2000